INDUSTRY

# Mastek

## BUY

IT

CMP (as on 07	0)	Rs 453	
<b>Target Price</b>		Rs 595	
Nifty			12,098
Sensex			41,142
KEY STOCK DATA	l l		
Bloomberg			MAST IN
No. of Shares (m	n)		24
MCap (Rs bn) / (\$	5 mn)		11/153
6m avg traded va	lue (Rs i	mn)	26
STOCK PERFORM	IANCE (9	%)	
52 Week high / l	ow	Rs	509/294
	3M	6N	l 12M
Absolute (%)	36.4	27.2	14.5
Relative (%)	35.2	15.1	. 3.2
SHAREHOLDING	PATTER	N (%)	
	Dec	-19	Dec-19*
Promoters	45	.43	38.45
FIs & Local MFs	12	.38	10.54
FPIs	6	5.52	5.55
Public & Others	35	6.67	45.46
Pledged Shares	25	.89	22.04
Source : BSE			
*post dilution SHP			

#### Amit Chandra

amit.chandra@hdfcsec.com +91-22-6171-7345

#### **Apurva Prasad**

apurva.prasad@hdfcsec.com +91-22-6171-7327

## Taking a big leap

Mastek announced the acquisition of Evosys in a two step transaction, which involves cash payout of USD 65mn and dilution of 17.5% in Mastek Ltd. The deal is valued at EV/EBITDA of 9.2x and P/E of 11.2x based on FY19 financials and 70% economic interest. The deal is EPS accretive and will boost FY21/22E EPS by 11.8/14.1% respectively. Post the traction, Evosys promoters will hold 15% in Mastek Ltd and 30% CCPS in TAISTech, converted to equity based on targets over the next three years. This is a complex traction but involves value unlocking and diversification of revenue. Risk involves higher dependence on Oracle and multi geography footprint, which the company has not handled before. We increase our TP to Rs 595 based on 9x (~18% discount to 5Y average) FY22E EPS plus Rs 31/sh for residual 4.7% stake in Majesco US.

#### **Details of the transaction**

- The deal involves two separate transactions. First is all cash buyout of the Evosys middle-east business by Mastek UK for a cash consideration of USD 65mn. The second transaction is Demerger of Evosys US+UK+RoW business and merging it into TAISTech (100% subsidiary of Mastek Ltd). As a result promoters of Evosys will get 15% stake in Mastek ltd resulting in a dilution of 17.5%.
- These are two separate transactions but we will have to view it as one deal and will value it based on the derived economic interest. The total revenue of Evosys is USD 60mn for FY19 with EBITDA margin of 22.9% and PAT margin of 18.8%.
- Mastek paid Rs 4.63bn (USD 65mn) in cash and Rs 1.62bn (15% stake value based on CMP) for the deal. The total consideration is Rs 6.25bn (USD 88mn) for an EBITDA/PAT of Rs 0.68/0.55bn based on 70% economic interest. The deal is valued at an EV/EBITDA and P/E of 9.2/11.2x based on FY19 financials.
- Mastek will fund the USD 65mn cash payout with a combination of debt and internal accruals. Mastek UK

will take a debt of USD 35mn (4% interest), USD 24mn from Majesco US stake sale and USD 6mn from internal accruals. The cash in the parent entity will remain at Rs 2.4bn and will not impact other income. The company will receive Rs 1.09bn from the residual Majesco US stake sale and Rs 0.40 bn from real estate monetisation. The net cash position post the transaction will reduce to Rs 1.60bn vs. Rs 4.30bn pre-transaction.

- Evosys, headquartered in Ahmedabad, was founded in 2006 by Umang Nahata and Rakesh Raman. Evosys is an Oracle platinum partner for implementation of ERP and HCM and SCM suites.
- Evosys has revenue is USD 70mn for FY20E with 1,300 employees and 300 customers. The revenue per employee is at 53.8K USD, which is healthy.
- Top-10 customers is 31% of revenue and has 100+ customers with revenue of more than USD 1bn. Evosys has 63% revenue from cloud and 55% of the revenue is repeat revenue. More than 25% of the clients have migrated to cloud and cloud revenue CAGR is 100% over FY16-19.
- Geographically the revenue is widely spread, Europe /Middle-East/US/APAC is 30/45/17/8% of revenue. Europe/US revenue has grown at a CAGR of 157/116% over FY17-19.

### **Financial Summary**

YE March (Rs bn)	FY18	FY19	FY20E	FY21E	FY22E
Net Revenues	8.17	10.33	10.74	16.59	18.76
EBIT	0.82	1.16	1.29	2.13	2.48
APAT	0.70	1.01	1.15	1.49	1.78
Diluted EPS (Rs)	27.7	39.9	40.3	52.3	62.4
P/E (x)	16.4	11.3	11.2	8.7	7.2
EV / EBITDA (x)	10.0	7.5	8.9	5.1	4.0
RoE (%)	13.7	15.9	15.1	17.2	17.5

Source: Company, HDFC sec Inst Research # Consolidated

HDFC securities Institutional Research is also available on Bloomberg ERH HDF <GO>& Thomson Reuters

EU/UK

30%

**HDFC** securities INSTITUTIONAL RESEARCH


Evosys revenue is evenly spread with strong presence in Middle-East and Europe

Europe presence is across Denmark and Netherlands

RoW include Australia, Singapore and India


Evosys revenue from cloud implementation has increased to 63% of revenue, which was just 20% in FY16

Annuity revenue stream is 32% while repeat revenue is 55% of revenue, which includes subscription and maintenance revenue



Source: Company, HDFC sec Inst Research,

Source: Company, HDFC sec Inst Research



## **Evosys Revenue Mix By Services (LTM May 19)** Licence, 7% Managed Services (Annuity),



Source: Company, HDFC sec Inst Research

Source: Company, HDFC sec Inst Research

32%



Based on our proforma calculation the revenue/EBIT/PAT increases by 50/79/35% for FY20E

EPS increase is 15% due to dilution impact

These numbers are not comparable with actual FY20E financials as the revenue will be split between FY20E and FY21E. We have assumed two months impact in FY20E and full year impact in FY21E

The net cash position post the transaction remains at Rs 1.60bn including Rs 1.09bn from Majesco US stake sale and Rs 0.40bn from real estate monetisation

### **Pre and Post Acquisition Proforma Financials**

Year ending March	FY20 (Pre)	EVOSYS (FY20)	FY20E (Post)	Change %
Net Revenues (USD mn)	139.7	70	209.6	50%
Net Revenues	9,873	4,983	14,856	50%
EBITDA	1,337	997	2,334	
EBITDA Margin %	14%	20%	16%	
Depreciation	225	114	339	
EBIT	1,112	883	1,994	<b>79%</b>
EBIT Margin (%)	11.3%	17.7%	13.4%	
Other Income (Including EO Items)	204		204	
Interest	33		144	
РВТ	1,282	883	2,054	60%
Tax (Incl Deferred)	276	225	501	
Minority Interest	-		197	
RPAT	1,006	658	1,356	35%
PAT Margin %	10.2%	13.2%	9.1%	
Adjusted EPS (Rs)	41.5		47.6	15%
No of Shares	24.3		28.5	17%
Source: Company, HDFC sec Inst Research				

Source: Company, HDFC sec Inst Research

FY20 (Pre)	FY20E (Post)
2,400	2,400
-	400
-	1,092
2,600	900
5,000	4,792
704	704
	2,492
4,296	1,596
	2,400 - - 2,600 <b>5,000</b> 704

Source: HDFC sec Inst Research

Split of Cash Payment to Evosys (USD mn)	
Debt Funded	35
Majesco stake Sale	24
Internal Accurals	6
Total	65

Source: Company, HDFC sec Inst Research

We increase FY20/21/22 revenue by 8.7/50.4/49.4% factoring in Evosys acquisition. FY20E includes two month impact and FY21E has full contribution from Evosys

EBIT margin for Evosys is at 20.7% which is higher than company average of 11%. The EBIT increase is 66.2/68.7% for FY21/22E

EPS improves by 11.8/14.1% for FY21/22E due to minority interest and dilution of equity by 17%

We have taken the residual value of 4.7% stake in Majesco US valued at Rs 1.09bn which is 38/sh

Particulars	Earlier estimates	Revised estimates	% change
FY20E			
Revenue (USD mn)	139.7	151.8	8.7
Revenue (Rs mn)	9.9	10.7	8.8
EBIT (Rs bn)	1.1	1.3	15.8
EBIT margin (%)	11.3	12.0	72 bps
EPS (Rs)	42.0	40.3	-4.1
FY21E			
Revenue (USD mn)	154.2	232.0	50.4
Revenue (Rs mn)	11.0	16.6	50.4
EBIT (Rs bn)	1.3	2.1	66.2
EBIT margin (%)	11.6	12.8	122 bps
EPS (Rs)	46.8	52.3	11.8
FY22E			
Revenue (USD mn)	172.0	257.0	49.4
Revenue (Rs mn)	12.6	18.8	49.4
EBIT (Rs bn)	1.5	2.5	68.7
EBIT margin (%)	11.7	13.2	151 bps
EPS (Rs)	54.7	62.4	14.1

#### Valuation

Per Share (Rs)
. ,
62
9
565
38
8
31
595
32%

INSTITUTIONAL RESEARCH

## Peer Set Comparison

Compony	МСар	СМР	ТР	RECO		EPS (	Rs)			P/E	(x)			RoE	(%)	
Company	(Rs bn)	(Rs)	(Rs)	RECO	FY19	FY20E	FY21E	FY22E	FY19	FY20E	FY21E	FY22E	FY19	FY20E	FY21E	FY22E
TCS	8,017	2,137	2,025	NEU	83.9	86.5	93.6	104.7	25.5	24.7	22.8	20.4	36.1	35.7	37.2	39.7
Infosys	3,300	777	850	BUY	37.1	38.2	43.5	48.1	20.9	20.4	17.9	16.2	24.3	25.4	28.2	28.3
Wipro	1,391	244	235	NEU	15.8	17.4	18.3	20.0	15.5	14.0	13.3	12.2	17.3	17.7	17.3	16.2
HCL Tech	1,648	608	665	BUY	37.3	39.0	41.7	48.2	16.3	15.6	14.6	12.6	26.0	23.2	21.0	20.7
TechM	796	825	910	BUY	48.9	49.7	54.3	62.7	16.9	16.6	15.2	13.2	22.0	21.1	21.0	21.2
Tier-1 IT Median									16.9	16.6	15.2	13.2	24.3	23.2	21.0	21.2
LTI	338	1,945	2,090	BUY	87.1	85.6	101.6	120.7	22.3	22.7	19.1	16.1	34.6	28.0	28.4	28.7
Mphasis	175	937	1,165	BUY	57.6	58.3	65.5	75.0	16.3	16.1	14.3	12.5	20.0	19.7	19.9	20.2
L&T Tech	176	1,688	1,790	BUY	67.8	76.0	86.6	103.7	24.9	22.2	19.5	16.3	32.0	29.4	28.4	28.5
Mindtree	152	922	830	NEU	44.1	38.5	48.0	63.3	20.9	23.9	19.2	14.6	24.9	18.3	22.7	26.0
Hexaware *	113	377	450	BUY	19.6	21.6	24.5	28.3	19.3	17.5	15.4	13.3	26.5	24.7	24.1	24.0
Cyient	55	487	490	NEU	43.6	36.3	40.9	46.0	11.2	13.4	11.9	10.6	19.5	15.3	15.9	16.2
Zensar	37	161	177	NEU	14.2	10.8	12.9	17.1	11.4	15.0	12.5	9.4	17.6	11.9	12.9	15.3
Persistent	54	710	745	BUY	47.8	47.1	50.0	59.6	14.8	15.1	14.2	11.9	15.7	14.4	15.2	16.2
Tata Elxsi	64	1,031	NA	NR	46.6	39.5	50.7	58.9	22.1	26.1	20.3	17.5	34.5	24.3	26.6	26.1
Sonata	36	345	422	BUY	23.7	28.5	31.6	36.3	14.5	12.1	10.9	9.5	35.1	36.1	35.3	35.7
Intellect	22	165	255	BUY	7.7	2.6	7.3	11.2	21.6	64.4	22.6	14.7	11.1	3.3	8.7	12.1
eClerx	23	634	NA	NR	61.7	52.0	53.7	57.0	10.3	12.2	11.8	11.1	17.6	14.0	14.7	14.6
Majesco	11	407	655	BUY	18.3	19.9	30.0	36.7	22.2	20.5	13.6	11.1	8.4	7.9	11.0	12.2
HGS	15	715	NA	NR	84.6	100.3	110.9	129.5	8.5	7.1	6.4	5.5	8.5	13.1	13.3	13.7
Mastek	11	453	595	BUY	39.9	40.3	52.3	62.4	11.3	11.2	8.7	7.2	15.9	15.1	17.2	17.5
Tier-2 IT Median									16.3	16.1	14.2	11.9	19.5	15.3	17.2	17.5

Source: HDFC sec Inst Research

## **HDFC** securities

INSTITUTIONAL RESEARCH

## **Income Statement (Consolidated)**

Year ending March	FY18	FY19	FY20E	FY21E	FY22E
Net Revenues (USD mn)	126.8	147.8	151.8	232.0	257.0
Growth (%)	51.8%	16.5%	2.7%	52.8%	10.8%
Net Revenues	8.17	10.33	10.74	16.59	18.76
Growth (%)	45.9%	26.4%	3.9%	54.5%	13.1%
Employee Expenses	4.81	5.87	5.93	9.21	10.14
Other Operating Expenses	2.36	3.12	3.28	4.78	5.63
EBITDA	1.00	1.34	1.53	2.59	3.00
Depreciation	0.19	0.17	0.25	0.47	0.51
EBIT	0.82	1.16	1.29	2.13	2.48
EBIT Margin (%)	10.0%	11.3%	12.0%	12.8%	13.2%
EBIT Growth (%)	126.7%	42.5%	10.6%	65.2%	16.8%
Other Income (Including EO Items)	0.20	0.23	0.19	0.24	0.30
Interest	0.06	0.06	0.05	0.14	0.16
РВТ	0.96	1.33	1.42	2.22	2.63
Tax (Incl Deferred)	0.26	0.32	0.31	0.51	0.60
Minority Interest	-	-	0.03	0.22	0.24
RPAT	0.70	1.01	1.08	1.49	1.78
EO (Loss) / Profit (Net Of Tax)	-	0.01	(0.07)	-	-
АРАТ	0.70	1.01	1.15	1.49	1.78
APAT Growth (%)	95.5%	44.3%	13.75%	29.8%	19.4%
Adjusted EPS (Rs)	27.7	39.9	40.3	52.3	62.4
EPS Growth (%)	<i>95.5%</i>	44.3%	0.9%	29.8%	19.4%

Source: Company, HDFC sec Inst Research

## **Balance Sheet (Consolidated)**

As at March (Rs bn)	FY18	FY19	FY20E	FY21E	FY22E
SOURCES OF FUNDS					
Share Capital - Equity	0.12	0.12	0.14	0.14	0.14
Reserves	5.37	7.04	7.87	9.21	10.79
Total Shareholders' Funds	5.49	7.16	8.01	9.35	10.93
Long Term Debt	0.50	0.69	3.18	3.19	3.19
Short Term Debt	0.20	0.01	0.01	0.01	0.01
Total Debt	0.70	0.70	3.19	3.20	3.20
Net Deferred Taxes	(0.34)	(0.16)	(0.16)	(0.16)	(0.16)
Other Non-current Liabilities & Provns	0.33	0.12	0.12	0.12	0.12
TOTAL SOURCES OF FUNDS	6.18	7.83	11.17	12.51	14.09
APPLICATION OF FUNDS					
Net Block	0.71	0.70	5.18	5.08	5.00
CWIP	0.02	0.01	0.01	0.01	0.01
Goodwill	1.08	0.98	0.98	0.98	0.98
Investments	1.66	2.82	1.11	1.11	1.11
Other Non-current Assets	0.11	0.15	0.15	0.15	0.15
Total Non-current Assets	3.59	4.66	7.43	7.33	7.24
Cash & Equivalents	2.06	2.07	2.40	2.78	4.01
Debtors	1.74	2.08	2.24	3.45	3.91
Other Current Assets	0.49	0.69	0.79	1.10	1.27
Total Current Assets	2.23	2.77	3.02	4.56	5.18
Creditors	0.19	0.09	0.10	0.16	0.18
Other Current Liabilities & Provns	1.50	1.58	1.59	1.99	2.16
Total Current Liabilities	1.69	1.68	1.69	2.15	2.34
Net Current Assets	0.54	1.09	1.34	2.40	2.84
TOTAL APPLICATION OF FUNDS	6.18	7.83	11.17	12.51	14.09

Source: Company, HDFC sec Inst Research

### **HDFC** securities

## **Cash Flow (Consolidated)**

Year ending March (Rs bn)	FY18	FY19	FY20E	FY21E	FY22E
Reported PBT	0.96	1.33	1.42	2.22	2.63
Non-operating & EO Items	(0.03)	(0.03)	(0.19)	(0.24)	(0.30)
Interest Expenses	0.06	0.06	0.05	0.14	0.16
Depreciation	0.19	0.17	0.25	0.47	0.51
Working Capital Change	(0.45)	(0.51)	(0.24)	(1.07)	(0.44)
Tax Paid	(0.09)	(0.31)	(0.31)	(0.51)	(0.60)
OPERATING CASH FLOW ( a )	0.64	0.73	0.98	1.01	1.96
Capex	(0.21)	(0.32)	(4.73)	(0.36)	(0.43)
Free Cash Flow (FCF)	0.43	0.41	(3.74)	0.65	1.52
Non-operating Income	0.04	0.02	1.90	0.24	0.30
INVESTING CASH FLOW ( b )	(0.17)	(0.30)	(2.83)	(0.13)	(0.13)
Debt Issuance/(Repaid)	0.04	0.01	2.49	0.01	0.01
Interest Expenses	(0.03)	(0.02)	(0.05)	(0.14)	(0.16)
FCFE	0.45	0.39	(1.30)	0.51	1.37
Share Capital Issuance	0.02	0.03	0.02	-	-
Dividend	(0.11)	(0.18)	(0.29)	(0.37)	(0.44)
FINANCING CASH FLOW ( c )	(0.07)	(0.16)	2.17	(0.51)	(0.60)
NET CASH FLOW (a+b+c)	0.40	0.27	0.33	0.37	1.23
EO Items, Others	(0.13)	0.25	-	-	-
Closing Cash & Equivalents	2.06	2.07	2.40	2.78	4.01

Source: Company, HDFC sec Inst Research

## **Key Ratios (Consolidated)**


	FY18	FY19	FY20E	FY21E	FY22E
PROFITABILITY (%)					
EBITDA Margin	12.3	12.9	14.3	15.6	16.0
APAT Margin	8.6	9.8	10.7	9.0	9.5
RoE	13.7	15.9	15.1	17.2	17.5
RoIC (or Core RoCE)	23.9	32.8	19.0	20.1	21.7
RoCE	12.5	15.1	12.5	13.5	14.3
EFFICIENCY					
Tax Rate (%)	27.1	23.9	21.7	23.0	23.0
Fixed Asset Turnover (x)	11.5	14.8	2.1	3.3	3.8
Debtors (days)	78	74	76	76	76
Other Current Assets (days)	22	24	27	24	25
Payables (days)	8	3	4	4	4
Other Current Liab & Provns (days)	67	56	54	44	42
Cash Conversion Cycle (days)	24	39	45	53	55
Debt/EBITDA (x)	0.7	0.5	2.1	1.2	1.1
Net D/E (x)	-0.2	-0.2	0.1	0.0	-0.1
Interest Coverage (x)	13.9	19.0	26.0	14.8	15.5
PER SHARE DATA (Rs)					
EPS	27.7	39.9	40.3	52.3	62.4
CEPS	35.1	46.8	48.9	68.7	80.5
Dividend	6.0	8.5	9.9	12.8	15.3
Book Value	217	283	281	328	384
VALUATION					
P/E (x)	16.4	11.3	11.2	8.7	7.2
P/BV (x)	2.1	1.6	1.6	1.4	1.2
EV/EBITDA (x)	10.0	7.5	8.9	5.1	4.0
EV/Revenues (x)	1.2	1.0	1.3	0.8	0.6
OCF/EV (%)	6.4	7.2	7.2	7.6	16.2
FCF/EV (%)	4.3	4.0	-27.4	4.9	12.6
FCFE/Mkt Cap (%)	3.9	3.4	-10.1	4.0	10.6
Dividend Yield (%)	1.3	1.9	2.2	2.8	3.4

Source: Company, HDFC sec Inst Research

**HDFC** securities

INSTITUTIONAL RESEARCH

#### **RECOMMENDATION HISTORY**



Date	СМР	Reco	Target
29-Mar-19	439	BUY	660
1-Apr-19	443	BUY	660
9-Apr-19	480	BUY	660
17-Apr-19	463	BUY	657
5-Jul-19	472	BUY	635
23-Jul-19	460	BUY	618
27-Aug-19	322	BUY	618
22-Sep-19	357	BUY	618
4-Oct-19	334	BUY	530
18-Oct-19	332	BUY	505
7-Jan-20	409	BUY	515
29-Jan-20	420	BUY	510
10-Feb-20	453	BUY	595

#### **Rating Definitions**

BUY: Where the stock is expected to deliver more than 10% returns over the next 12 month periodNEUTRAL: Where the stock is expected to deliver (-)10% to 10% returns over the next 12 month periodSELL: Where the stock is expected to deliver less than (-)10% returns over the next 12 month period



#### Disclosure:

We, **Amit Chandra**, **MBA & Apurva Prasad**, **MBA**, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. HSL has no material adverse disciplinary history as on the date of publication of this report. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Research Analyst or his/her relative or HDFC Securities Ltd. does not have any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate does not have any material conflict of interest.

#### Any holding in stock –No

HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475.

#### Disclaimer:

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.

This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from t date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.

HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066

Compliance Officer: Binkle R. Oza Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600

HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: CA0062; SEBI Research Analyst Reg. No.: INH000002475; SEBI Investment Adviser Reg. No.: INA000011538; CIN - U67120MH2000PLC152193

Mutual Funds Investments are subject to market risk. Please read the offer and scheme related documents carefully before investing.

MASTEK: COMPANY UPDATE